Tag Archives: EMA

The LentiGlobin application for cMAA at the EMA from bluebird bio still in review process by CHMP

LONDON, 27-Mar-2019 — /EPR HEALTHCARE NEWS/ — The LentiGlobin application for Conditional Marketing Authorization (cMAA) at the EMA from bluebird bio is still in the process of being reviewed by CHMP during their 25-28 March 2019 meeting. An opinion for the cMAA is expected to be released soon.

SOURCE: EuropaWire

Logos: